Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 2177-2184

  Mäkitie, Antti A ^a   MacMillan, Christina ^a,d   Ho, James ^a   Shi, Wei ^a,c   Lee, Andrew ^a,c   O'Sullivan, Brian ^a,c   Payne, David ^a,c   Pintilie, Melania ^a   Cummings, Bernard ^a,c   Waldron, John ^a,c   Warde, Padraig ^a,c   Irish, Jonathan ^a,b   Brown, Dale ^a,b   Gilbert, Ralph ^a,b   Gullane, Patrick ^a,b   Liu, Fei Fei ^a,c   Kamel Reid, Suzanne ^a,b,c,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN P16; RETINOBLASTOMA PROTEIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; VIRUS DETECTION; VIRUS INFECTION;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RETINOBLASTOMA PROTEIN; RNA, VIRAL;

EID: 0037838642     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Mendenhall, W., Million, R., Mancuso, A., and Stringer, S. Nasopharynx. In: Million, R. R., Cassis, N. J., and C. Million (ed.), Management of Head and Neck Cancer - A Multidisciplinary Approach, pp. 599-626. Philadelphia: JB Lippincott Co., 1994.
2. Lee, N., Xia, P., Quivey, J. M., Sultanem, K., Poon, I., Akazawa, C., Akazawa, P., Weinberg, V., and Fu, K. K. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys., 53: 12-22, 2002.
3. Chow, E., Payne, D., O'Sullivan, B., Pintilie, M., Liu, F. F., Waldron, J., Warde, P., and Cummings, B. Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. Is combined modality treatment really necessary? Radiother. Oncol., 63: 269-274, 2002.
4. Waldron, J., Tin, M., Keller, A., Lum, C., Japp, B., Sellmann, S., van Prooijen, M., Gitterman, L., Blend, R., Payne, D., Liu, F-F., Warde, P., Cummings, B., Pintilie, M., and O'Sullivan, B. Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma. Radiother. Oncol., in press.
5. Sultanem, K., Shu, H. K., Xia, P., Akazawa, C., Quivey, J. M., Verhey, L. J., and Fu, K. K. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int. J. Radiat. Oncol. Biol. Phys., 48: 711-722, 2000.
6. Al-Sarraf, M., LeBlanc, M., Giri, P. G., Fu, K. K., Cooper, J., Vuong, T., Forastiere, A. A., Adams, G., Sakr, W. A., Schuller, D. E., and Ensley, J. F. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol., 16: 1310-1317, 1998.
7. Huncharek, M., and Kupelnick, B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1, 528 patients from six randomized trials. Am. J. Clin. Oncol., 25: 219-223, 2002.
8. Group., I. N. C. S. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int. J. Radiat. Oncol. Biol. Phys., 35: 463-469, 1996.
9. Chan, A., Teo, P., Leung, T., Leung, S., Lee, W., Yeo, W., Choi, P., and Johnson, P. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 33: 569-577, 1995.
10. Sobin, L., and Wittekind, C. (eds.). TNM Classification of Malignant Tumours, Ed. 5. New York: A John Wiley & Sons, 1997.
11. Shi, W., Pataki, I., MacMillan, C., Pintilie, M., Payne, D., O'Sullivan, B., Cummings, B. J., Warde, P., and Liu, F-F. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer (Phila.), 94: 1997-2006, 2002.
12. Su, C. K., and Wang, C. C. Prognostic value of Chinese race in nasopharyngeal cancer. Int. J. Radiat. Oncol. Biol. Phys., 54: 752-758, 2002.
13. Harn, H. J., Hsieh, H. F., Ho, L. I., Yu, C. P., Chen, J. H., Chiu, C. C., Fan, H. C., and Lee, W. H. Apoptosis in nasopharyngeal carcinoma as related to histopathological characteristics and clinical stage. Histopathology, 33: 117-122, 1998.
14. Kouvidou, C., Stefanaki, K., Dai, Y., Tzardi, M., Koutsoubi, K., Darivianaki, K., Karidi, E., Rontogianni, D., Zois, E., Kakolyris, S., Georgoulias, V., Delides, G., and Kanavaros, P. p21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression. Anticancer Res., 17: 2615-2620, 1997.
15. Niedobitek, G., Agathanggelou, A., Barber, P., Smallman, L. A., Jones, E. L., and Young, L. S. P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J. Pathol., 170: 457-461, 1993.
16. Porter, M. J., Field, J. K., Lee, J. C. K., Leung, S. F., Lo, D., and Van Hasselt, C. A. Detection of the tumour suppressor gene p53 in nasopharyngeal carcinoma in Hong Kong Chinese. Anticancer Res., 14: 1357-1360, 1994.
17. Tsai, S. T., Jin, Y. T., Leung, H. W., Wang, S. T., Tsao, C. J., and Su, I. J. Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas. Anticancer Res., 18: 2849-2854, 1998.
18. Liggett, W. H., Jr., Sewell, D. A., Rocco, J., Ahrendt, S. A., Koch, W., and Sidransky, D. p16 and p16 β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res., 56: 4119-4123, 1996.
19. Serrano, M. The tumor suppressor protein p16INK4a. Exp. Cell Res., 237: 7-13, 1997.
20. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrendt, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sidransky, D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56: 3630-3633, 1996.
21. Olshan, A. F., Weissler, M. C., Pei, H., Conway, K., Anderson, S., Fried, D. B., and Yarbrough, W. G. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene, 14: 811-818, 1997.
22. Gessner, C., Liebers, U., Kuhn, H., Stiehl, P., Witt, C., Schauer, J., and Wolff, G. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur. Respir. J., 19: 134-140, 2002.
23. Hilton, D. A., Penney, M., Evans, B., Sanders, H., and Love, S. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am. J. Surg. Pathol., 26: 472-478, 2002.
24. Rocco, J. W., and Sidransky, D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp. Cell Res., 264: 42-55, 2001.
25. Gulley, M. L., Nicholls, J. M., Schneider, B. G., Amin, M. B., Ro, J. Y., and Geradts, J. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am. J. Pathol., 152: 865-869, 1998.
26. Shibosawa, E., Tsutsumi, K., Koizuka, I., Hoshikawa, M., and Takakuwa, T. Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas. Laryngoscope, 110: 93-97, 2000.
27. Baba, Y., Tsukuda, M., Mochimatsu, I., Furukawa, S., Kagata, H., Satake, K., Koshika, S., Nakatani, Y., Hara, M., Kato, Y., and Nagashima, Y. Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma. Cancer Detect. Prev., 25: 414-419, 2001.
28. Huang, G. W., Mo, W. N., Kuang, G. Q., Nong, H. T., Wei, M. Y., Sunagawa, M., and Kosugi, T. Expression of p16, nm23-H1. Ecadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope, 111: 1465-1471, 2001.
29. Yang, X., He, Z., Xin, B., and Cao, L. LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16INK4a expression. Oncogene, 19: 2002-2013, 2000.
30. Shanmugaratnam, K., Chan, S. H., de The, G., Goh, J. E. H., Khor, T. H., Simon, M. J., and Tye, C. Y. Histopathology of nasopharyngeal carcinoma. Cancer (Phila.), 44: 1029-1044, 1979.
31. Li, J. H., Li, P., Klamut, H., and Liu, F. F. Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines. Clin. Cancer Res., 3: 507-514, 1997.
32. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
33. Lo, K-W., Cheung, S-T., Leung, S-F, van Hasselt, A., Tsang, Y-S., Mak, K-F., Chung, Y-F., Woo, J., Lee, J. C. K., and Huang, D. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res., 56: 2721-2725, 1996.
34. Marks, J. E., Phillips, J. L., and Menck, H. R. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer (Phila.), 83: 582-588, 1998.
35. Niedobitek, G., Hansmann, M., Herbst, H., Young, L., Dienemann, D., Hartmann, C., Finn, T., Pitteroff, S., Welt, A., Anagnostopoulos, I., Friedrich, R., Lobeck, H., Sam, C., Araujo, I., Rickinson, A., and Stein, H. Epstein-Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J. Pathol., 165: 17-24, 1991.
36. Gulley, M. L., Burton, M. P., Allred, D. C., Nicholls, J. M., Amin, M. B., Ro, J. Y., and Schneider, B. G. Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Hum. Pathol., 29: 252-259, 1998.
37. Choi, P. H., Suen, M. W., Huang, D. P., Lo, K. W., and Lee, J. C. Nasopharyngeal carcinoma: genetic changes, Epstein-Barr virus infection, or both. A clinical and molecular study of 36 patients. Cancer, 72: 2873-2878, 1993.
38. Wang, G. L., Lo, K. W., Tsang, K. S., Chung, N. Y., Tsang, Y. S., Cheung, S. T., Lee, J. C., and Huang, D. P. Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br. J. Cancer, 81: 1122-1126, 1999.